KDIGO 2021慢性肾脏病儿童血压管理临床实践指南解读

doi:10.12372/jcp.2022.21e1610

Abstract

Abstract:

Hypertension is an important complication of chronic kidney disease (CKD) and substantial cause for the occurrence and progression of CKD. In 2021, the Kidney Disease: Improving Global Outcomes (KDIGO) published clinical practice guideline for the management of blood pressure in CKD, which is mainly applicable to CKD patients who have not undergone dialysis. The content includes methods, control objectives and treatment of blood pressure measurement in CKD children. This article interprets the relevant content of the blood pressure management of CKD children in the guideline.

Key words: chronic kidney disease, blood pressure, guide interpretation, child

ZHANG Pei, GAO Chunlin, XIA Zhengkun. Comments on KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease of Children[J].Journal of Clinical Pediatrics, 2022, 40(6): 469-474.

Figures/Tables 1

References 33

[1]	Amy CW, Joseph TF. Blood pressure in children with chronic kidney disease: lessons learned from the Chronic Kidney Disease in Children Cohort Study[J]. Pediatr Nephrol, 2020, 35(7): 1203-1209. doi: 10.1007/s00467-019-04288-6
[2]	Parekh RS, Carroll CE, Wolfe RA, et al. Cardiovascular mortality in children and young adults with end-stage kidney disease[J]. J Pediatr, 2002, 141(2): 191-197. doi: 10.1067/mpd.2002.125910
[3]	Brady TM, Roem J, Cox C, et al. Adiposity, sex, and cardiovascular disease risk in children with CKD: A Longitudinal Study of Youth Enrolled in the Chronic Kidney Disease in Children (CKiD) Study[J]. Am J Kidney Dis, 2020, 76(2): 166-173. doi: 10.1053/j.ajkd.2020.01.011
[4]	Groothoff JW, Offringa M, Grootenhuis M, et al. Long-term consequences of renal insufficiency in children: lessons learned from the Dutch LERIC study[J]. Nephrol Dial Transplant, 2018, 33(4): 552-560. doi: 10.1093/ndt/gfx190
[5]	Kidney Disease: Improving Global Outcomes KDIGO Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease[J]. Kidney Int, 2021, 99(3S): S1-S87.
[6]	Flynn JT, Daniels SR, Hayman LL, et al. Update: ambulatory blood pressure monitoring in children and adolescents: a scientific statement from the American Heart Association[J]. Hypertension, 2014, 63(5): 1116-1135. doi: 10.1161/HYP.0000000000000007
[7]	Halbach S. Practical application of ABPM in the pediatric nephrology clinic[J]. Pediatr Nephrol, 2020, 35(11): 2067-2076. doi: 10.1007/s00467-019-04361-0 pmid: 31732802
[8]	Ku E, Mc Culloch CE, Warady BA, et al. Twenty-four-hour ambulatory blood pressure versus clinic blood pressure measurements and risk of adverse outcomes in children with CKD[J]. Clin J Am Soc Nephrol, 2018, 13(3): 422-428. doi: 10.2215/CJN.09630917
[9]	中国高血压防治指南修订委员会. 中国高血压防治指南 2018 年修订版[J]. 心脑血管病防治, 2019, 19(1): 21.
[10]	Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical practice guideline for screening and management of high blood pressure in children: and adolescents[J]. Pediatrics, 2017, 140(3): e20171904. doi: 10.1542/peds.2017-1904
[11]	Muntner P, Shimbo D, Carey RM, et al. Measurement of blood pressure in humans: A Scientific Statement From the American Heart Association[J]. Hypertension, 2019, 73(5): e35-e66.
[12]	Warady BA, Abraham AG, Schwartz GJ, et al. Predictors of rapid progression of glomerular and nonglomerular kidney disease in children and adolescents: the Chronic Kidney Disease in Children (CKiD) cohort[J]. Am J Kidney Dis, 2015, 65(6): 878-88. doi: 10.1053/j.ajkd.2015.01.008
[13]	Lurbe E, Torró I, Álvarez J, et al. Impact of ESH and AAP hypertension guidelines for children and adolescents on office and ambulatory blood pressure-based classifications[J]. J Hypertens, 2019, 37(12): 2414-2421. doi: 10.1097/HJH.0000000000002229
[14]	Parati G, Stergiou GS, Asmar R, et al. European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring[J]. J Hypertens, 2008, 26(8): 1505-1526. doi: 10.1097/HJH.0b013e328308da66
[15]	Stergiou G, Stambolliu E, Bountzona I, et al. Home blood pressure monitoring in children and adolescents: systematic review of evidence on clinical utility[J]. Curr Hypertens Rep, 2019, 21(8): 64. doi: 10.1007/s11906-019-0967-2 pmid: 31240404
[16]	Kidney Disease: Improving Global Outcomes KDIGO Blood Pressure Work Group. KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease[J]. Kidney Int Suppl, 2012, 2(5):372-376.
[17]	ESCAPE Trial Group, Wuhl E, Trivelli A, et al. Strict blood-pressure control and progression of renal failure in children[J]. N Engl J Med, 2009, 361(17): 1639-1650. doi: 10.1056/NEJMoa0902066
[18]	Atkinson MA, Ng DK, Warady BA, et al. The CKiD study: overview and summary of findings related to kidney disease progression[J]. Pediatr Nephrol, 2021, 36(3): 527-538. doi: 10.1007/s00467-019-04458-6
[19]	Joseph TF, Megan KC, Derek KN, et al. Achieved clinic blood pressure level and chronic kidney disease progression in children: a report from the Chronic Kidney Disease in Children cohort[J]. Pediatr Nephrol, 2021, 36(6): 1551-1559. doi: 10.1007/s00467-020-04833-8 pmid: 33200315
[20]	Kogon AJ, Pierce CB, Cox C, et al. Nephrotic-range proteinuria is strongly associated with poor blood pressure control in pediatric chronic kidney disease[J]. Kidney Int, 2014, 85(4): 938-944. doi: 10.1038/ki.2013.352 pmid: 24048375
[21]	Lurbe E, Agabiti-Rosei E, Cruickshank JK, et al. 2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents[J]. J Hypertens, 2016, 34(10): 1887-920. doi: 10.1097/HJH.0000000000001039
[22]	Alfred KC, Tara IC, William CC, et al. Blood pressure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference[J]. Kidney Int, 2019, 95(5): 1027-1036. doi: S0085-2538(19)30107-3 pmid: 31010478
[23]	Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents[J]. Pediatrics, 2017, 140(3): e20171904. doi: 10.1542/peds.2017-1904
[24]	Hari P, Sahu J, Sinha A, et al. Effect of enalapril on glomerular filtration rate and proteinuria in children with chronic kidney disease: a randomized controlled trial[J]. Indian Pediatr, 2013, 50(10): 923-928. doi: 10.1007/s13312-013-0262-2
[25]	Seeman T, Gilik J, Vondrak K, et al. Regression of left-ventricular hypertrophy in children and adolescents with hypertension during ramipril monotherapy[J]. Am J Hypertens, 2007, 20(9): 990-996. pmid: 17765141
[26]	Xie X, Liu Y, Perkovic V, et al. Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials[J]. Am J Kidney Dis, 2016, 67(5): 728-741. doi: 10.1053/j.ajkd.2015.10.011
[27]	Clase CM, Carrero JJ, Ellison DH, et al. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference[J]. Kidney Int, 2020, 97(1): 42-61. doi: 10.1016/j.kint.2019.09.018
[28]	Clase CM, Barzilay J, Gao P, et al. Acute change in glomerular ﬁltration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes[J]. Kidney Int, 2017, 91(3): 683-690. doi: 10.1016/j.kint.2016.09.038
[29]	Bandak G, Sang Y, Gasparini A, et al. Hyperkalemia after initiating renin-angiotensin system blockade: The Stockholm Creatinine Measurements (SCREAM) Project[J]. J Am Heart Assoc, 2017, 6(7): e005428. doi: 10.1161/JAHA.116.005428
[30]	Jun M, Jardine MJ, Perkovic V, et al. Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: A general practice-based, observational study[J]. PLoS One, 2019, 14(3): e0213192. doi: 10.1371/journal.pone.0213192
[31]	Ahmed AK, Kamath NS, El Kossi M, et al. The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease[J]. Nephrol Dial Transplant, 2010, 25(12): 3977-3982. doi: 10.1093/ndt/gfp511
[32]	Tobe SW, Clase CM, Gao P, et al. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies[J]. Circulation, 2011, 123(10): 1098-1107. doi: 10.1161/CIRCULATIONAHA.110.964171
[33]	Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy[J]. N Engl J Med, 2013, 369(20): 1892-1903. doi: 10.1056/NEJMoa1303154

项目	蛋白尿程度（推荐等级）	是否伴糖尿病（推荐等级）
CKD（G1-G4）伴高血压	重度（A3）	无（1B）
	中度（A2）	无（2C）
	中度（A2）;重度（A3）	有（1B）

Comments on KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease of Children

RichHTML

PDF (PC)

Like

Knowledge

Cited

Abstract

Cite this article

share this article

Figures/Tables 1

References 33

Related Articles 15

Metrics

Comments

Recommended 0

[1]	LIN Jinfeng, CHEN Yi, DENG Yan, FENG Ai, HUANG Juan, CHEN Lizhu, XIE Jingqi, NIE Xiaojing. A comparative study on the detection of anti-Nephrin antibodies in children's nephrotic syndrome by chemiluminescence method and cell-based assay [J]. Journal of Clinical Pediatrics, 2026, 44(8): 682-689.
[2]	ZHENG Fangyuan, WANG Miao, DING Mingming, LU Aidong, JIA Yueping, ZENG Huimin, ZHANG Leping. Next-generation sequencing identified gene variants and their prognostic impact in pediatric Philadelphia chromosome positive acute lymphoblastic leukemia [J]. Journal of Clinical Pediatrics, 2026, 44(8): 690-697.
[3]	ZHANG Xiao, FANG Hongjun, KUANG Xiaojun, WANG Lijuan, WU Zhao, JIANG Sha, LI Pei, WU Liwen. Analysis of the clinical and electrophysiological characteristics of atonic seizures in children [J]. Journal of Clinical Pediatrics, 2026, 44(8): 698-704.
[4]	WANG Mengqian, YANG Hui. Case series analysis of 13 intestinal Behcet’s syndrome in children [J]. Journal of Clinical Pediatrics, 2026, 44(8): 705-711.
[5]	WU Xirong, GAO Qi, GUO Siyuan, YIN Qingqin, QIN Qiang, YIN Ju, JIAO Anxia, CHEN Chenghao, WU Di, WANG Bei, DUAN Xiaomin, PENG Yun, XU Baoping, GAO Liwei. Clinical characteristics and prognosis of pulmonary mucormycosis in children with diabetes mellitus [J]. Journal of Clinical Pediatrics, 2026, 44(8): 712-720.
[6]	HAN Yanan, GE Lanlan, CUI Jieyuan. A case report of branchio-oto-renal syndrome caused by EYA1 gene variant with a 6-year follow-up [J]. Journal of Clinical Pediatrics, 2026, 44(8): 721-726.
[7]	SHI Jiayi, GAO Chunlin, JIA Lili, LU Yunyun, SUN Tao, ZHU Xiaodong, XIA Zhengkun, ZHANG Pei. Phenotypic characteristics and prognostic analysis of a pedigree with childhood isolated nephrotic syndrome caused by compound heterozygous mutations in the COQ2 gene [J]. Journal of Clinical Pediatrics, 2026, 44(8): 727-732.
[8]	Rachel Rosen, Osvaldo Borrelli, Christophe Faure, Katja Karrento, Usha Krishnan, Samuel Nurko, Nathalie Rommel, Alan Silverman, Michiel van Wijk, Marc Benninga (Author), Chinese Medical Association Parenteral and Enteral Nutrition Branch Pediatrics Group, The Subspecialty Group of Gastroenterology, The Society of Pediatric, Chinese Medical Association, Gastroenterology Group, Pediatrician Branch, Chinese Medical Doctor Association (Translator). Core interpretation and explanation of Rome Ⅴ diagnostic criteria: upper gastrointestinal disorders of gut-brain interaction in children and adolescents [J]. Journal of Clinical Pediatrics, 2026, 44(7): 595-608.
[9]	Carlo Di Lorenzo, Miguel Saps, Bruno P. Chumpitazi, Shaman Rajindrajith, Annamaria Staiano, Nikhil Thapar, Miranda van Tilburg, Carlos Velasco-Benítez, Arine Vlieger (Author), Chinese Medical Association Parenteral and Enteral Nutrition Branch Pediatrics Group, The Subspecialty Group of Gastroenterology, The Society of Pediatric, Chinese Medical Association, Gastroenterology Group, Pediatrician Branch, Chinese Medical Doctor Association (Translator). Core interpretation and explanation of Rome Ⅴ diagnostic criteria: lower and biliary disorders of gut-brain interaction in children and adolescents [J]. Journal of Clinical Pediatrics, 2026, 44(7): 609-621.
[10]	LI Xufeng, TANG Haoxun, LI Xingjun, ZHANG Lize, GAO Chenqing, ZHAO Shunying, LIU Jianhua. Clinical characteristics, chest CT imaging phenotypes, and their correlation with prognosis in 76 children with Chlamydia pneumoniae pneumonia [J]. Journal of Clinical Pediatrics, 2026, 44(7): 622-627.
[11]	WANG Zhen, SHAO Jingbo, ZHANG Na, XIA Min, ZHU Jiashi, DU Chengkan, LI Hong. Factors influencing long-term recurrence in pediatric acute lymphoblastic leukemia patients with low-risk disease at initial diagnosis: a five-year follow-up analysis of 254 cases from a single center [J]. Journal of Clinical Pediatrics, 2026, 44(7): 628-635.
[12]	GUO Xuemei, XUE Yao, WANG Yongren, RONG Liucheng, FANG Yongjun, LIN Rufeng. Clinical features and prognosis of childhood acute myeloid leukemia with CBFA2T3::GLIS2 fusion [J]. Journal of Clinical Pediatrics, 2026, 44(7): 636-643.
[13]	YANG Lijun, FU Dongxia, CUI Yan, YANG Junmei, ZHANG Liming. Clinical manifestation and genetic analysis of CHARGE syndrome caused by CHD7 gene variation [J]. Journal of Clinical Pediatrics, 2026, 44(7): 644-650.
[14]	HU Yan, YANG Fan, LIANG Aimin, MAO Meng. Identification and management of faltering growth in children: insights from the 13th International Conference on Nutrition and Growth [J]. Journal of Clinical Pediatrics, 2026, 44(6): 485-488.
[15]	LIU Ziyao, WANG Congying, WANG Hongmao, ZHANG Mingming, XU Yingjie, LAI Jianming, NIU Wenquan, LI Xiaohui. Early differentiation of Kawasaki disease with joint symptoms and systemic juvenile idiopathic arthritis with Kawasaki disease-like symptoms: a single-center retrospective study [J]. Journal of Clinical Pediatrics, 2026, 44(6): 489-498.